ABSTRACT
Genetic research on nicotine dependence has utilized multiple assessments that are in weak agreement. We conducted a genome-wide association study of nicotine dependence defined using the Diagnostic and Statistical Manual of Mental Disorders (DSM-NicDep) in 61,861 individuals (47,884 of European ancestry, 10,231 of African ancestry, 3,746 of East Asian ancestry) and compared the results to other nicotine-related phenotypes. We replicated the well-known association at the CHRNA5 locus (lead SNP: rs147144681, p =1.27E-11 in European ancestry; lead SNP = rs2036527, p = 6.49e-13 in cross-ancestry analysis). DSM-NicDep showed strong positive genetic correlations with cannabis use disorder, opioid use disorder, problematic alcohol use, lung cancer, material deprivation, and several psychiatric disorders, and negative correlations with respiratory function and educational attainment. A polygenic score of DSM-NicDep predicted DSM-5 tobacco use disorder and 6 of 11 individual diagnostic criteria, but none of the Fagerström Test for Nicotine Dependence (FTND) items, in the independent NESARC-III sample. In genomic structural equation models, DSM-NicDep loaded more strongly on a previously identified factor of general addiction liability than did a “problematic tobacco use” factor (a combination of cigarettes per day and nicotine dependence defined by the FTND). Finally, DSM-NicDep was strongly genetically correlated with a GWAS of tobacco use disorder as defined in electronic health records, suggesting that combining the wide availability of diagnostic EHR data with nuanced criterion-level analyses of DSM tobacco use disorder may produce new insights into the genetics of this disorder.
Competing Interest Statement
J.G. is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists", filed January 24, 2018.
Funding Statement
We acknowledge the following sources of support: K01DA051759 (ECJ); T32DA007261 (JVB); K01DA058807 (JDD); K01AA031724 (APM); R01DA054869 (AA, HJE, JG); DP1DA054394, T32IR5226 (SSR); R01DA042755, U01DA042217, R01AG077742, R01DA054087, R01DA044283, DA05147, DA13240, DA02441, AA09367, AA11886, MH066140 (TE, AG, EAW, SV, MM, JJL); R01DA030976 (KCW, IRG); R01MH100141 (PNRV); R01MH123489, R01MH123619, R01MH134284 (ARD); AUS NHMRC 464914 (IBH, NGM); R00DA023549 (NAG); HSRI 67-095 (VS). LD acknowledges support from NHMRC Investigator Grant L3 (2016825), NHMRC Senior Principal Research Fellowship (1135991), the National Drug and Alcohol Research Centre (NDARC), UNSW funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. The AGDS was primarily funded by National Health and Medical Research Council (NHMRC) of Australia (Grant No. APP1086683) to N.G.M. This work was further supported by NHMRC grants (No. 1145645, 1078901 and 1087889). N.G.M. is supported by a NHMRC Investigator Grant (No. APP1172990). GBP: Data collection was funded and data analysis was supported by the Australian National Health and Medical Research Council (No. APP1138514) to S.E.M. S.E.M. is supported by a National Health and Medical Research Council Investigator Grant (No. APP1172917). The Psychiatric Genomics Consortium's Substance Use Disorders (PGC-SUD) Working Group receives support from the National Institute on Drug Abuse via R01DA054869. We gratefully acknowledge prior support from the National Institute on Alcohol Abuse and Alcoholism and support from National Institutes of Mental Health to the overall PGC. Statistical analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Washington University School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest J.G. is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. There are no other conflicts of interest to disclose.
Author list and affiliations have been updated.
Data Availability
Upon publication, summary statistics from this study will be made available at the following website for those who agree to follow the data access terms and conditions: https://pgc.unc.edu/for-researchers/download-results/
